

MedGenome raises Series E funding of \$47.5 M to expand access to genomics offerings in India

21 July 2025 | News

To broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets



Bengaluru-based genomic diagnostics and research services company MedGenome has raised \$47.5million in its Series E funding round, co-led by Maj Invest, a private equity firm joining as a new investor, along with existing investor Novo Holdings. The round also saw participation from Sofina, an existing shareholder in the company.

This funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets. The announcement also reiterates MedGenome's mission to help reduce India's disease burden through early detection and targeted disease management using genetic and integrated diagnostics tools with high affordability.

Speaking about this funding aligning with the company's vision, Dr Vedam Ramprasad, CEO of MedGenome, said, "India's healthcare ecosystem is increasingly recognizing the transformative potential of genomics, driving innovation and enhancing the country's healthcare capabilities. This fundraise also reflects the growing adoption of genomics in personalized and preventive healthcare in India as well as other emerging economies. At MedGenome, we combine cutting-edge science with real-world application, bringing advanced omics solutions that bridge the unmet need in disease diagnosis and management. Early genomics-led intervention not only helps the patient but also helps families manage the economic and emotional burden of a disease."

Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, commented, "Our reinvestment in MedGenome reflects our belief in the company's potential to transform the landscape of genetic and integrated diagnostics in India and beyond. MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets."

"With its robust genomics portfolio, commitment to science and the transformative impact it has had on healthcare, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We're proud to support

their next phase of growth, expanding their solutions to more markets in India and worldwide" Jannick Dam Mortensen, Partner, Maj Invest Minorities, added.